1 BTC
=
- USD
Intuitive Surgical Inc.
As of June 25, 2026 at 06:13 UTC
Chart
About Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
ISRG in Bitcoin terms
Intuitive Surgical Inc. is tracked on Roxom Terminal for users who want to follow and trade global stocks in a Bitcoin-denominated market environment.
- Intuitive Surgical Inc. is categorized under ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES.
- BTC-denominated charting frames stock performance against Bitcoin instead of fiat alone.
- The global terminal hub links individual stock pages into a crawlable BTC-native market map.
Market Statistics
Trading Metrics
How to Buy ISRG
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ISRG
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesWhile Nvidia leads the AI revolution with a 31x P/E ratio, Intuitive Surgical trades at 50x P/E but appears cheaper relative to its historical 70x average. The surgical robotics leader generates recurring revenue from parts and services (75% of revenue) supporting its da Vinci robots, offering more stable long-term growth than Nvidia's competitive chip market. With expanding FDA approvals for new applications, Intuitive Surgical presents a compelling growth opportunity for aggressive investors.
Ken Griffin's Citadel Advisors reduced positions in Nvidia and Amazon during Q1 while increasing its stake in Intuitive Surgical by 30.3%. Despite the medical device company facing headwinds from competition, lower margins on new products, and tariffs, analysts believe its strong competitive moat, large addressable market, and AI integration potential make it an attractive long-term investment at current valuations.
The article recommends three healthcare dividend stocks for long-term investors: Bristol Myers Squibb, Merck, and Medtronic. Despite facing recent challenges like patent cliffs and competitive pressures, all three companies have strong dividend track records with consistent payout increases and promising pipelines to drive future growth.
Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trials of AT7687, its lead GIPR antagonist candidate for obesity treatment.
Medtronic received FDA approval for its Hugo robotic-assisted surgery platform for urologic procedures in December 2025, marking its entry into a market dominated by Intuitive Surgical's da Vinci system. While Medtronic faces significant competitive headwinds due to Intuitive's 26-year head start, massive installed base of 11,395 systems, and broader procedure approvals, the robotic surgery market is projected to grow from $13.8 billion to $63.7 billion by 2035. Medtronic's Hugo is already approved in 35+ countries with procedure volumes growing 2-3x faster than the market, suggesting the company can grow alongside the expanding market without necessarily overtaking the leader.